glp-1 news updates november 2025 ISPOR 2025: Exploring reasons for discontinuation 🚨 Breaking News in Obesity

This precision approach helps patients and providers select optimal GLP-1 therapy based on individual genetic factors rather than insurance coverage limitations

Diarrhea or constipation may intensify

This provides a dedicated space for users to process their emotional journey and mental well-being while on GLP-1 medication

Food and Drug Administration issued a warning letter citing sterility failures, subpotent injectable and ophthalmic drugs, and insanitary production conditions at its Pennsylvania facility

Mistake 3: not holding sublingual drops long enough The minimum hold time is 2 minutes

Weight Loss-Independent Effect of Liraglutide on Insulin Sensitivity in Individuals with Obesity and Pre-Diabetes